Merck sees up to $7 billion in sales of COVID-19 drug through end of 2022
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Merck (MRK) PT Raised to $90 at Morgan Stanley on Gardasil Strength
October 29, 2021 8:46 AM EDTMorgan Stanley analyst Matthew Harrison raised the price target on Merck (NYSE: MRK) to $90.00 (from $88.00) while maintaining a Equalweight rating after 3Q total revenue beat expectations driven primarily by Gardasil sales due to strong global demand and increased supply. Management expects robust... More
